Hemorrhage

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-04-23
EMA Authorised: Praxbind (idarucizumab) — Boehringer Ingelheim International GmbH
EMA authorised Praxbind (idarucizumab) for hemorrhage. Boehringer Ingelheim International GmbH is the marketing authorisation holder; decisi…